Beyond Statins: Evolving Therapeutic Options for Dyslipidemia Management

Activity Title: Beyond Statins: Evolving Therapeutic Options for Dyslipidemia Management

PROGRAM OVERVIEW
Beyond Statins: Evolving Therapeutic Options for Dyslipidemia Management aims to provide healthcare professionals with a comprehensive understanding of the mechanisms of action of various non-statin therapies for managing different types of dyslipidemias. Participants will enhance their ability to apply evidence-based decision making in selecting appropriate therapies tailored to individual patient needs, evaluate the integration of emerging therapies into clinical practice and discuss strategies to improve the overall knowledge and performance of the healthcare team.

ACTIVITY TYPE
Internet Enduring Activity

NLA ID:
2025024

ACTIVITY DATES
Release Date: July 1, 2025
Expiration Date: January 1, 2026

TARGET AUDIENCE
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, advanced practice registered nurses, nurse practitioners and registered dietitians seeking to develop an expertise in clinical lipidology.

LEARNING OBJECTIVES
At the Conclusion of this activity, participants should be able to:

• Describe the mechanisms of action of various non-station therapies in managing several types of dyslipidemias.
• Apply evidence-based decision-making to select appropriate therapies beyond statins for patients with dyslipidemias, considering patient-specific factors such as LDL-C targets, comorbidities, and treatment tolerability.
• Evaluate the potential for integrating emerging therapies into clinical practice to optimize lipid management and reduce cardiovascular risk in statin-intolerant or high-risk patients.
• Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. The deadline to claim credit is January 1, 2026.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

*IMPORTANT* Pharmacists MUST request credit before January 1, 2026. Credit requested after this date will be subject to a fee by the accreditation board.
For Dietitians: Upon completion of the activity evaluation form, dietitians may submit evaluations of the quality of activities/materials to CDR. Poor evaluations of activities/materials may trigger an audit of the activities/ materials by CDR.

COMMERCIAL SUPPORT
This educational activity has been provided with support by educational grants from Regeneron Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Esperion, Amgen and Novartis.

CREDIT DESIGNATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CME credit provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Physician Credit Designation Statement
The National Lipid Association designates this enduring internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.

DietitiansThe National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 2.0 continuing professional education units (CPEUs) for completion of this program/ materials.

Pharmacists
Universal Activity Number UAN JA0007192-0000-25-019-H01-P
This Activity has been approved for 2.0 contact hour(s) (.20CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
The maximum number of hours awarded for this CE activity is 2.0 contact hours.
For the advanced practice nurse, this activity has 0.75 contact hours of pharmacotherapy content.

Name	Relationship	Company
Christie M. Ballantyne, MD, FNLA- Co-chair	Contracted Research	Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, NIH, AHA, ADA.
	Consultant	89Bio, Abbott Diagnostics, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken*, Esperion, Genentech, Gilead, Illumina, Ionis, Lilly, Matinas BioPharma Inc, Merck, New Amsterdam*, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic
Kaye Eileen Willard, MD, FNLA- Co-chair	Nothing to disclose.
Anne Carol Goldberg, MD, MNLA	Principal Investigator	Amgen, Arrowhead, IONIS/SIS, Marea, New Amsterdam, Novartis, Esperion, 89Bio, Sanofi
	National Coordinating Investigator	New Amsterdam
	National Lead Investigator	IONIS
	Committee Member	Eli Lilly, New Amsterdam
Kathy Byrne, CRNP, FPCNA, FNLA, CLS	Nothing to disclose.
Scott Merryman, MD, FNLA	Nothing to disclose.
Kellie McLain, ANP-C, CLS, FNLA	Speaker	Esperion
	Advisory Committee	New Amsterdam
Gisette Reyes-Soffer, MD	Consultant	Eli Lilly
	Investigator	Kaneka
Dan Soffer, MD, MNLA	Consultant	Amgen, Amryt, Endless Health, GeninCode, Heartflow, Ionis, PHAR, New Amsterdam, Regeneron
	Investigator	Akcea, Amryt, Arrowhead, Ionis, Lilly, Novartis, PCORI, NIH, Heartflow
James A. Underberg, MD, MS, MNLA	Speaker	Amgen, Esperion, Regeneron
	Consultant	Amgen
	Advisory Board	Ionis, New Amsterdam
	Steering Committee Member	Chiese
Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA	Nothing to disclose.
Zahid Ahmad, MD, FNLA	Contracted Research	US Department of Defense, National Institute of Health
	Investigator	Ionis
	Chair, Adjudication Committee	Amyrt
Michael J. Wilkinson, MD, FNLA	Consultant	Amarin, Regeneron, The Kinetix Group, Novartis, Kaneka
	Advisory Board	Novartis
	Investigator	Amgen
	Speaker	Regeneron
NLA	N/A	The National Lipid Association Staff has Nothing to disclose..

Name	Relationship	Company
Daniel Gaudet, MD, PhD	Contracted Research	Alnylam, Amgen, Applied Therapeutics, Arrowhead, AstraZeneca, 89Bio, Boehringer-Ingelhein, Chiesi (Amryt), DalCor Pharma, Eli Lilly, Esperion, Inversago, Ionis, Kowa, Medison, Merck, New Amsterdam, Novo Nordisk, The Medicine Company, Ultragenyx, Uniqure, Verve Therapeutics
	Consultant	CRISPR Therapeutics, Flagship Pioneering, Medison, Novartis, Rona Therapeutics
Ann Marie Navar, MD, PhD	Contracted Research	Amgen, Arrowhead, AstraZeneca, Bayer, Eli Lilly, Esperion, Janssen, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Roche, Silence Therapeutics
	Investigator	Amgen, Esperion, Jansen
Steve E. Nissen, MD, MACC	Nothing to disclose.
Marlys L. Koschinsky, PhD, FAHA, FNLA, FCAHS, FACC, OOnt, FRSC	Advisory Board	Novartis Board
	Presenter	Vindico CME
	Consultant	Novartis, Eli Lilly
	Contracted Research	Novartis, Eli Lilly
Samuel Klein, MD	Advisory Committee	Merck, Abbvie, Regeneron, Lilly, Boerhinger Ingelheim, Verdiva
Kausik Ray, MD, FMedSci	Advisory/Consultant	Amgen, Sanofi, Regeneron, Pfizer, Viatris, Abbott, AstraZeneca, Lilly, Kowa Pharmaceuticals, Novo Nordisk, Boehringer Ingelheim, Esperion, Cargene Therapeutics, Resverlogix, Novartis, Silence Therapeutics, NewAmsterdam Pharma, Scribe Therapeutics, CRISPR Therapeutics, VAXXINITY, Amarin, CSL Behring, Bayer, Cleerly Health, EmendoBio
	Speaker	Novartis, Amgen, Amarin, Viatris, Novo Nordisk, Boehringer Ingelheim, Daiichi Sankyo, Kyrka, AstraZeneca
	Contracted Research	Regeneron, Amgen, Sanofi, Daiichi Sankyo, MSD, Pfizer, Ultragenyx
	Stock	Pemi31 Therapeutics, NewAmsterdam Pharma

Name	Relationship	Company
Susan Halli Demeter, DNP, FNLA, Vice-Chair	Speaker	PCNA, ACC
Scott Webster Shurmur, MD, FNLA, Vice-Chair	Consultant	Akcea
Elizabeth Urteaga, PharmD, BCADM, Vice-Chair	Nothing to disclose.
B Alan Bottenberg, DO, FACOI, FNLA	Nothing to disclose.
Jamie Burkle, MD, FNLA	Consultant	Regeneron, Novartis
	Speaker	Amgen, Esperion, Boehringer Ingelheim, Pfizer
Kathleen H. Byrne, CRNP, MS, CLS, FNLA	Nothing to disclose.
Jonathan Eddinger, MD	Nothing to disclose.
Pamela Papp, APRN, FNLA	Nothing to disclose.

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of the uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME. All disclosures have been reviewed and resolved at this time.

DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

PERMISSIONS
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

---